| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
113,172,000 |
| Market
Cap: |
411.95(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.33 - $21.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8.7 |
| Insider 3/6 Months : 9.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
41,099 |
41,099 |
41,099 |
| Total Buy Value |
$0 |
$200,765 |
$200,765 |
$200,765 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
36,927 |
64,644 |
119,052 |
614,411 |
| Total Sell Value |
$111,396 |
$309,620 |
$961,613 |
$14,187,856 |
| Total People Sold |
4 |
6 |
7 |
9 |
| Total Sell Transactions |
10 |
23 |
35 |
64 |
| End Date |
2025-05-25 |
2025-02-21 |
2024-08-23 |
2023-08-24 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wilson Martin |
General Counsel |
• • – |
2025-08-19 |
4 |
S |
$3.00 |
$1,762 |
D/D |
(588) |
135,462 |
|
-28% |
|
| Militello John |
See Remarks |
• • – |
2025-08-19 |
4 |
S |
$3.00 |
$1,082 |
D/D |
(361) |
55,924 |
|
-28% |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-08-19 |
4 |
S |
$3.00 |
$2,412 |
D/D |
(805) |
221,609 |
|
-28% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-08-18 |
4 |
S |
$3.07 |
$3,077 |
D/D |
(1,004) |
136,050 |
|
-23% |
|
| Militello John |
See Remarks |
• • – |
2025-08-18 |
4 |
S |
$3.07 |
$2,142 |
D/D |
(699) |
56,285 |
|
-23% |
|
| Shah Gaurav |
CEO |
• • – |
2025-08-18 |
4 |
D |
$3.05 |
$6,814 |
D/D |
(2,234) |
784,572 |
|
- |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-08-18 |
4 |
S |
$3.07 |
$5,149 |
D/D |
(1,680) |
222,414 |
|
-23% |
|
| Militello John |
See Remarks |
• • – |
2025-08-14 |
4 |
S |
$3.02 |
$21,263 |
D/D |
(7,043) |
56,984 |
|
-23% |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-08-14 |
4 |
S |
$3.02 |
$33,695 |
D/D |
(11,161) |
224,094 |
|
-23% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-08-14 |
4 |
S |
$3.02 |
$36,557 |
D/D |
(12,109) |
137,054 |
|
-23% |
|
| Stevens Christopher James |
Chief Operating Officer |
• • – |
2025-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
407,166 |
407,166 |
|
- |
|
| Ondrey Aaron |
Chief Financial Officer |
• • – |
2025-07-03 |
4 |
S |
$2.88 |
$4,257 |
D/D |
(1,477) |
128,173 |
|
-29% |
|
| Southwell David P |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
31,660 |
|
- |
|
| Dolsten Mikael |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
44,220 |
|
- |
|
| Wong Roderick |
|
• • • |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
47,667 |
47,667 |
|
- |
|
| Granadillo Pedro P |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
54,734 |
54,734 |
|
- |
|
| Boess Carsten |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Makker Gotham |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
I/I |
49,434 |
415,346 |
|
- |
|
| Pratumsuwan Piratip |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Malik Fady Ibraham |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Bjork Elisabeth |
|
• • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Shah Gaurav |
CEO |
• • – |
2025-05-20 |
4 |
S |
$6.45 |
$14,523 |
D/D |
(2,253) |
786,806 |
|
46% |
|
| Patel Kinnari |
See Remarks |
• • – |
2025-05-20 |
4 |
S |
$6.45 |
$4,944 |
D/D |
(767) |
441,927 |
|
46% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-05-20 |
4 |
S |
$6.45 |
$3,784 |
D/D |
(587) |
149,163 |
|
46% |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-05-20 |
4 |
S |
$6.45 |
$5,163 |
D/D |
(801) |
235,255 |
|
46% |
|
194 Records found
|
|
Page 1 of 8 |
|
|
0.09 (2.41%) 
